SCHEMBL496596

SCHEMBL496596

O=C(O)c1cccnc1NCC1CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 3/20 0.54
DHODH Q02127 4/20 0.53
ASPH Q12797 1/20 0.49
KDM8 Q8N371 1/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
RAB9A P51151 4/20 0.48
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.46
LMNA P02545 2/20 0.46
GAA P10253 1/20 0.46
HTT P42858 2/20 0.45
NPC1 O15118 3/20 0.45
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3716905 0.88 ALDH1A1 (0.62) KDM4CMEN1KMT2ARAB9AKDM4E
Ammonia Solution, Strong SCHEMBL5757646 0.83 F10 (0.58) KDM4CDHODHKMT2ABDKRB1
SCHEMBL2713154 0.82 KDM4E (0.59) KDM4CASPHKDM8RAB9AKDM4E
SCHEMBL3714496 0.82 KDM4E (0.59) KDM4CASPHKDM8RAB9AKDM4E
SCHEMBL4611285 0.82 DHODH (0.60) DHODHMEN1KMT2ARAB9AKDM4E
SCHEMBL11646854 0.80 PRKCQ (0.42) KDM4CMEN1KMT2ARAB9AKDM4E
SCHEMBL31678687 0.79 KDM4E (0.46) ASPHKDM8KDM4EALDH1A1HPGD
SCHEMBL2179962 0.78 DHODH (0.58) DHODHMEN1KMT2ARAB9AKDM4E
SCHEMBL4611740 0.78 DHODH (0.58) DHODHMEN1KMT2ARAB9AKDM4E
SCHEMBL6168326 0.78 DHODH (0.58) DHODHMEN1KMT2ARAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 KDM4C 2791/4885DHODH 1463/4885ASPH 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.